Martin Auster
Stock Analyst at UBS
(2.16)
# 2,696
Out of 4,837 analysts
47
Total ratings
51.61%
Success rate
4.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $59.93 | +100.23% | 7 | Sep 18, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $99 → $105 | $37.35 | +181.12% | 7 | Mar 16, 2022 | |
| FULC Fulcrum Therapeutics | Initiates: Outperform | $26 | $6.52 | +299.08% | 1 | Mar 22, 2021 | |
| SLDB Solid Biosciences | Maintains: Neutral | $105 → $120 | $2.95 | +3,967.80% | 4 | Mar 16, 2021 | |
| GLTO Galecto | Maintains: Outperform | $725 → $300 | $3.00 | +9,900.00% | 2 | Mar 16, 2021 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $49 → $58 | $10.07 | +475.97% | 3 | Mar 10, 2021 | |
| UTHR United Therapeutics | Maintains: Outperform | $169 → $196 | $309.57 | -36.69% | 4 | Feb 22, 2021 | |
| ALXO ALX Oncology Holdings | Maintains: Outperform | $62 → $98 | $0.43 | +22,754.48% | 2 | Feb 11, 2021 | |
| INSM Insmed | Maintains: Outperform | $50 → $60 | $68.51 | -12.42% | 2 | Jan 19, 2021 | |
| SRRK Scholar Rock Holding | Initiates: Outperform | $65 | $31.54 | +106.09% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $39.99 | +82.55% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $4.28 | - | 2 | Dec 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $15.31 | +409.47% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $0.91 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $6.38 | +574.51% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $34 | $31.64 | +7.46% | 1 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $9.67 | +117.17% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $21.10 | -24.17% | 1 | May 7, 2020 |
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $59.93
Upside: +100.23%
Ultragenyx Pharmaceutical
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $37.35
Upside: +181.12%
Fulcrum Therapeutics
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $6.52
Upside: +299.08%
Solid Biosciences
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $2.95
Upside: +3,967.80%
Galecto
Mar 16, 2021
Maintains: Outperform
Price Target: $725 → $300
Current: $3.00
Upside: +9,900.00%
Stoke Therapeutics
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $10.07
Upside: +475.97%
United Therapeutics
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $309.57
Upside: -36.69%
ALX Oncology Holdings
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $0.43
Upside: +22,754.48%
Insmed
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $68.51
Upside: -12.42%
Scholar Rock Holding
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $31.54
Upside: +106.09%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $39.99
Upside: +82.55%
Dec 10, 2020
Downgrades: Underperform
Price Target: n/a
Current: $4.28
Upside: -
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $15.31
Upside: +409.47%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $0.91
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $6.38
Upside: +574.51%
Jul 7, 2020
Initiates: Outperform
Price Target: $34
Current: $31.64
Upside: +7.46%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $9.67
Upside: +117.17%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $21.10
Upside: -24.17%